Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Monks

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Pediatric Blood & Cancer|April 2, 2014
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistanceDavid J Monsma, David M Cherba, Patrick J Richardson, et al.
American Journal of Cancer Research|June 24, 2015
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanismsDavid J Monsma, David M Cherba, Emily E Eugster, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Molecular Cancer Therapeutics|August 2, 2018
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate CancerSong Cho, Francesca Zammarchi, David G Williams, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Pediatric Blood & Cancer|April 2, 2014
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistanceDavid J Monsma, David M Cherba, Patrick J Richardson, et al.
American Journal of Cancer Research|June 24, 2015
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanismsDavid J Monsma, David M Cherba, Emily E Eugster, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Molecular Cancer Therapeutics|August 2, 2018
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate CancerSong Cho, Francesca Zammarchi, David G Williams, et al.
Pageof 5